Clinical standards for the diagnosis and management of asthma in low- and middle-income countries
dc.contributor.author | Jayasooriya S | |
dc.contributor.author | Stolbrink M | |
dc.contributor.author | Khoo EM | |
dc.contributor.author | Sunte IT | |
dc.contributor.author | Awuru JI | |
dc.contributor.author | Cohen M | |
dc.contributor.author | Lam DC | |
dc.contributor.author | Spanevello A | |
dc.contributor.author | Visca D | |
dc.contributor.author | Centis R | |
dc.contributor.author | Migliori GB | |
dc.contributor.author | Ayuk AC | |
dc.contributor.author | Buendia JA | |
dc.contributor.author | Awokola BI | |
dc.contributor.author | Del-Rio-Navarro BE | |
dc.contributor.author | Muteti-Fana S | |
dc.contributor.author | Lao-Araya M | |
dc.contributor.author | Badellino H | |
dc.contributor.author | Somwe SW | |
dc.contributor.author | Anand MP | |
dc.contributor.author | Garcí-Corzo JR | |
dc.contributor.author | Bekele A | |
dc.contributor.author | Soto-Martinez ME | |
dc.contributor.author | Ngahane BHM | |
dc.contributor.author | Ngahane BHM | |
dc.contributor.author | Florin M | |
dc.contributor.author | Voyi K | |
dc.contributor.author | Tabbah K | |
dc.contributor.author | Bakki B | |
dc.contributor.author | Alexander A | |
dc.contributor.author | Garba BL | |
dc.contributor.author | Salvador EM | |
dc.contributor.author | Fischer GB | |
dc.contributor.author | Falade AG | |
dc.contributor.author | ŽivkoviĆ Z | |
dc.contributor.author | Romero-Tapia SJ | |
dc.contributor.author | Erhabor GE | |
dc.contributor.author | Zar H | |
dc.contributor.author | Gemicioglu B | |
dc.contributor.author | Brandão HV | |
dc.contributor.author | Kurhasani X | |
dc.contributor.author | El-Sharif N | |
dc.contributor.author | Singh V | |
dc.contributor.author | Ranasinghe JC, Kudagammana ST, Masjedi MR, Velásquez JN, Jain A, Cherrez-Ojeda I, Valdeavellano LFM, Gómez RM, Mesonjesi E, Morfin-Maciel BM, Ndikum AE, Mukiibi GB, Reddy BK, Yusuf O, Taright-Mahi S, Mérida-Palacio JV, Kabra SK, Nkhama E, Filho NR, Zhjegi VB, Mortimer K, Rylance S, Masekela RR. | |
dc.date.accessioned | 2024-11-28T14:06:53Z | |
dc.date.available | 2024-11-28T14:06:53Z | |
dc.date.issued | 2023-09-01 | |
dc.description.abstract | BACKGROUND: The aim of these clinical standards is to aid the diagnosis and management of asthma in low-resource settings in low- and middle-income countries (LMICs).METHODS: A panel of 52 experts in the field of asthma in LMICs participated in a two-stage Delphi process to establish and reach a consensus on the clinical standards.RESULTS: Eighteen clinical standards were defined: Standard 1, Every individual with symptoms and signs compatible with asthma should undergo a clinical assessment; Standard 2, In individuals (>6 years) with a clinical assessment supportive of a diagnosis of asthma, a hand-held spirometry measurement should be used to confirm variable expiratory airflow limitation by demonstrating an acute response to a bronchodilator; Standard 3, Pre- and post-bronchodilator spirometry should be performed in individuals (>6 years) to support diagnosis before treatment is commenced if there is diagnostic uncertainty; Standard 4, Individuals with an acute exacerbation of asthma and clinical signs of hypoxaemia or increased work of breathing should be given supplementary oxygen to maintain saturation at 94-98%; Standard 5, Inhaled short-acting beta-2 agonists (SABAs) should be used as an emergency reliever in individuals with asthma via an appropriate spacer device for metered-dose inhalers; Standard 6, Short-course oral corticosteroids should be administered in appropriate doses to individuals having moderate to severe acute asthma exacerbations (minimum 3-5 days); Standard 7, Individuals having a severe asthma exacerbation should receive emergency care, including oxygen therapy, systemic corticosteroids, inhaled bronchodilators (e.g., salbutamol with or without ipratropium bromide) and a single dose of intravenous magnesium sulphate should be considered; Standard 8, All individuals with asthma should receive education about asthma and a personalised action plan; Standard 9, Inhaled medications (excluding dry-powder devices) should be administered via an appropriate spacer device in both adults and children. Children aged 0-3 years will require the spacer to be coupled to a face mask; Standard 10, Children aged <5 years with asthma should receive a SABA as-needed at step 1 and an inhaled corticosteroid (ICS) to cover periods of wheezing due to respiratory viral infections, and SABA as-needed and daily ICS from step 2 upwards; Standard 11, Children aged 6-11 years with asthma should receive an ICS taken whenever an inhaled SABA is used; Standard 12, All adolescents aged 12-18 years and adults with asthma should receive a combination inhaler (ICS and rapid onset of action long-acting beta-agonist [LABA] such as budesonide-formoterol), where available, to be used either as-needed (for mild asthma) or as both maintenance and reliever therapy, for moderate to severe asthma; Standard 13, Inhaled SABA alone for the management of patients aged >12 years is not recommended as it is associated with increased risk of morbidity and mortality. It should only be used where there is no access to ICS.The following standards (14-18) are for settings where there is no access to inhaled medicines. Standard 14, Patients without access to corticosteroids should be provided with a single short course of emergency oral prednisolone; Standard 15, Oral SABA for symptomatic relief should be used only if no inhaled SABA is available. Adjust to the individual's lowest beneficial dose to minimise adverse effects; Standard 16, Oral leukotriene receptor antagonists (LTRA) can be used as a preventive medication and is preferable to the use of long-term oral systemic corticosteroids; Standard 17, In exceptional circumstances, when there is a high risk of mortality from exacerbations, low-dose oral prednisolone daily or on alternate days may be considered on a case-by-case basis; Standard 18. Oral theophylline should be restricted for use in situations where it is the only bronchodilator treatment option available.CONCLUSION: These first consensus-based clinical standards for asthma management in LMICs are intended to help clinicians provide the most effective care for people in resource-limited settings. | |
dc.identifier.citation | Jayasooriya S, Stolbrink M, Khoo EM, Sunte IT, Awuru JI, Cohen M, Lam DC, Spanevello A, Visca D, Centis R, Migliori GB, Ayuk AC, Buendia JA, Awokola BI, Del-Rio-Navarro BE, Muteti-Fana S, Lao-Araya M, Chiarella P, Badellino H, Somwe SW, Anand MP, Garcí-Corzo JR, Bekele A, Soto-Martinez ME, Ngahane BHM, Florin M, Voyi K, Tabbah K, Bakki B, Alexander A, Garba BL, Salvador EM, Fischer GB, Falade AG, ŽivkoviĆ Z, Romero-Tapia SJ, Erhabor GE, Zar H, Gemicioglu B, Brandão HV, Kurhasani X, El-Sharif N, Singh V, Ranasinghe JC, Kudagammana ST, Masjedi MR, Velásquez JN, Jain A, Cherrez-Ojeda I, Valdeavellano LFM, Gómez RM, Mesonjesi E, Morfin-Maciel BM, Ndikum AE, Mukiibi GB, Reddy BK, Yusuf O, Taright-Mahi S, Mérida-Palacio JV, Kabra SK, Nkhama E, Filho NR, Zhjegi VB, Mortimer K, Rylance S, Masekela RR. Clinical standards for the diagnosis and management of asthma in low- and middle-income countries. Int J Tuberc Lung Dis. 2023 Sep 1;27(9):658-667. https://doi. 10.5588/ijtld.23.0203. PMID: 37608484; PMCID: PMC10443788. | |
dc.identifier.uri | https://dspace.alquds.edu/handle/20.500.12213/9546 | |
dc.language.iso | en_US | |
dc.publisher | Int J Tuberc Lung Dis. | |
dc.title | Clinical standards for the diagnosis and management of asthma in low- and middle-income countries | |
dc.type | Article |